Adity Singh, Saurav S Ghosal, KM. Diksha S Singh, Manoj Mishra, Jayant Kumar Maurya
Adity Singh1*, Saurav S Ghosal1, KM. Diksha S Singh2, Dr. Manoj Mishra2, Jayant Kumar Maurya3
1Department of Pharmaceutics, Shambhunath Institute of Pharmacy, Jhalwa, Prayagraj, Uttar Pradesh - 211012, India.
2Department of Pharmacology, Shambhunath Institute of Pharmacy, Jhalwa, Prayagraj, Uttar Pradesh - 211012, India.
3Ashok Singh Pharmacy College, Jaunpur, Uttar Pradesh, India.
Volume - 14,
Issue - 9,
Year - 2021
The aim of present study is to development of novel formulation present unique challenge. The topical route has long been used for delivering drugs directly to the affected target site through the skin. Current approaches in design and optimization of topical formulation necessitate extensive decisions in choosing the right components for the formulation to achieve high safety clinical efficacy and patient compliance it was concluded that etodolac emulgel formula could be very promising topical alternative for the conventional dosages from provide sustained and prolonged delivery of drugs. The results of this research establish a new and useful approach in designing the oil phase of a formulation where the active ingredient needs to be dissolved in the oil phase and develop emulgel system. Additionally, the use of emulgels for topical delivery of hydrophobic drugs has been found to be better at achieving a higher drug concentration over a longer period of time across the skin barrier as compared to gels.
Cite this article:
Adity Singh, Saurav S Ghosal, KM. Diksha S Singh, Manoj Mishra, Jayant Kumar Maurya. A Novel approach to develop Etodolac Emulgel with Alkaloidal Penetration Enhancer. Research Journal of Pharmacy and Technology. 2021; 14(9):4868-4. doi: 10.52711/0974-360X.2021.00846
Adity Singh, Saurav S Ghosal, KM. Diksha S Singh, Manoj Mishra, Jayant Kumar Maurya. A Novel approach to develop Etodolac Emulgel with Alkaloidal Penetration Enhancer. Research Journal of Pharmacy and Technology. 2021; 14(9):4868-4. doi: 10.52711/0974-360X.2021.00846 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-9-60
1. Alfonso R. Gennaro, Remington: The Science and Practice of Pharmacy, 17th edition, Mack Publishing Company; 1985 Chapter No. 11 Pharmaceutical and Medicinal agents, P. 1644-1661.
2. Bacchi, S., et al., Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review. Vol. 11. 2012. 52-64.
3. Carstensen J.T., 1996. Preformulation. In: Banker G.S., Rhodes C.T., Editors. Modern Pharmaceutics. 3rd edition. New York: Marcel Dekker; Vol. 72 Drug and The Pharmaceutical Sciences, pp. 213-37.
4. Chein YW. Novel drug delivery systems: Fundamentals, development, concepts and biomedical application. Marcel Dekker, New York, 1981; P. 139-217, 301-380.
5. Davis, J.S., et al., Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic. Open heart, 2017. 4(1): p. e000550.
6. Dickson, D., A double-blind evaluation of topical piroxicam gel with oral ibuprofen in osteoarthritis of the knee. Curr Ther Res., 1991. 49: p. 199-207.
7. Gopinath R., Naidu R.A.S., 2011. Pharmaceutical Preformulation studies – current review. Int J Pharm Biological Arc, Vol. 2, Issue 5, pp. 1391-1400
8. Gupta GD, Gaud RS. Release rate of Nimesulide from different gellants. Ind J Pharm Sci 1999; 61: 229-234.
9. Gupta GD, Gaud RS. Release rate of Tenoxicam from Acrypol gel. The Indian Pharmacist 2005; 69- 76.
10. Margaret N, Mutimer CR, Hill JA, Murray E. Modern ointment base technology comparative evaluation of bases. J American Pharm Association 1956; 4: 212- 217.
11. Nair R, Sevukarajan M, Mohammed B, and Kumar J (2010). Formulation of Microemulsion based vaginal gel in-vitro and in-vivo evaluation. Der Pharmacia Lettre, 2: 99-105.
12. P. Sridhara Babu, M. Guravaiah, I. Hatti, K. Srikanth. Qualitative analysis of capsaicin from chillies and chilli powder by H.P.L.C method. Int. J. Curr. Res. Chem. Pharma. Sci. 2014, 1(6): 184-194.
13. Patel J, Trivedi J, Chudhary S (2014). Formulation and evaluation of diacerein emulgel for psoriatic arthritis. Int J Pharm Res Bio-Sci, 3: 625-638.
14. Prajapati MK., Patel MR., Patel KR., Patel NM. Emulgel: a novel Approach to topical drug delivery. International Journal Univ Pharm Bio Sci. 2013; 2(1): 134-148
15. Rajesh Asija, Nitin Nama, Deepak Sharma Development and evaluation of novel Fluticasone Propionate Emulgel for topical drug delivery. Journal of Chemical and Pharmaceutical Research, 2015, 7(2): 772-780.
16. Ricciotti, E. and G.A. Fitz Gerald, Prostaglandins and Inflammation. Arteriosclerosis, thrombosis, and vascular biology, 2011. 31(5): p. 986-1000.
17. Robinson RJ, Lee VH. Controlled Drug Delivery: Fundamental and Application. 2nd edition, Marcel Dekker, New York; 1987: Chapter-1”Influence of drug properties and routes of drug administration on the design of sustained and controlled release systems” P 4-61.
18. Sanjay, Jain BD, Padsalg A, Patel K, Mokale V. Formulation development and evaluation of fluconazole gel in various polymer bases. Asn J Pharm 2007; 1: 63- 68.
19. SB Shirsand, MS Para, D Nagendrakumar, KM Kanani and D Keerthy. Formulation and evaluation of Ketoconazole niosomal gel drug delivery system. Int J Pharm Investig. 2012; 2(4); 201- 207.
20. Snehal P. Mulye, Kiran A. Wadkar and Manish S. Kondawar Formulation development and evaluation of Indomethacin emulgel. Der Pharmacia Sinica, 2013, 4(5): 31-45
21. Tadicherla, S. and Berman, B. (2006). Percutaneous dermal drug delivery for local pain control. Ther Clin Risk Manag. 2(1): 99-113.
22. Technologie 10(3): 30-46.
23. Tushar L., Akhilesh D., Prabhakara P., Kamath J.V., 2012. Preformulation studies of controlled/sustained release formulations: an review. Int Res J Pharmacy, Vol. 3, Issue 5, pp. 95-99.
24. V Singla; S Saini; AC Rana, Emulgel: a new platform for topical drug delivery. Int Pharma Sci., 2012, 2(3), 36-44.
25. V. K. Singh, V. K. Mishra, J. K. Maurya, S. K. Singh, A. Mishra. Formulation and Evaluation of Cephalexin Monohydrate Reconstitutional Oral Suspension with Piperine and Their Antibacterial activity. World Journal of Pharmaceutical Research, 2014, 3(5), 821-831.
26. Wadke P.A., Jacobson S., 1980. Preformulation Testing In: Liberman H.A. and Lachman L., Editors. Pharmaceutical Dosage Forms-Tablets, Vol-I, New York: Marcel Dekker, pp. 1-42.
27. Wallace, J.L., et al., NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology, 2000. 119(3): p. 706-14.
28. Walters KA. Dermatological and transdermal formulation. Florida CRC Press. 2002; ( 403): 323-327.
29. Walters, K. A. (1986). Percutaneous absorption and transdermal therapie. Pharm.
30. Whittle, B.J., Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol, 2003. 17(3): p. 301-13.
31. Woodford, R. and Barry, B. W. (1986). Penetration enhancers and the percutaneous absorption of drugs: an update. J Toxicol Cut Ocular Toxicol. 5: 167-77